We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Canadian diagnostics company Nanostics released interim trial data showing its ClarityDX prostate test is 147 percent more specific than the prostate-specific antigen (PSA) blood test for predicting clinically significant prostate cancer.
A new study evaluating Cardiologs’ deep learning tool for identifying patients at risk for atrial fibrillation (AFib) showed that it outperformed regular 12-lead electrocardiogram (ECG) testing.
Miami, Fla.-based DermaSensor said two studies of its handheld skin cancer detection device — which could become the first FDA-cleared device of its kind for use by primary care physicians — have demonstrated the device’s efficacy.